OCM
CERO

Oaktree Capital Management’s CERo Therapeutics CERO Stock Holding History

Oaktree Capital Management’s Portfolio CERO Stock Details CERO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-100
Closed -$1.98M – 371
2021
Q4 		$1.98M Buy
+100
New +$1.99M 0.02% 240

Other funds holding CERO

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

Oaktree Capital Management's CERO Position: Q1 2022 in Review

Oaktree Capital Management sold out of CERo Therapeutics (CERO) in Q1 2022, closing a stake of 100 shares — an estimated $1.98M sold.

Oaktree Capital Management first reported a position in CERO in Q4 2021 and held it in 1 quarter. The position peaked at $1.98M in Q4 2021. 45 funds tracked by Wall St. Rank hold CERO as of Q1 2022.

  • Oaktree Capital Management reported no remaining CERo Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Oaktree Capital Management sold 100 CERo Therapeutics shares in Q1 2022, an estimated $1.98M.
  • Oaktree Capital Management first reported a position in CERo Therapeutics in Q4 2021 and held it in 1 quarter.
  • Oaktree Capital Management's CERo Therapeutics position peaked at $1.98M in Q4 2021.
  • 45 funds tracked by Wall St. Rank held CERo Therapeutics as of Q1 2022.

Based on Oaktree Capital Management's 13F filing for Q1 2022, filed 16 May 2022.